Determinants of alcohol use and abuse: impact of quantity and frequency patterns on liver disease

Hepatology

Volumn 46, Issue 6, 2007, Pages 2032-2039

  Zakhari, Samir ^a   Li, Ting Kai ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACAMPROSATE; ALCOHOL; ALCOHOL DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; CLOMETHIAZOLE; CYTOCHROME P450 2E1; DISULFIRAM; LACTIC ACID; LORAZEPAM; NALTREXONE; NICOTINAMIDE ADENINE DINUCLEOTIDE; PARACETAMOL; PROTEINASE INHIBITOR; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; TETRABAMATE; URIC ACID;

ACIDOSIS; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALCOHOL BLOOD LEVEL; ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ALCOHOL METABOLISM; ALCOHOL WITHDRAWAL; ALCOHOLISM; CARBOHYDRATE METABOLISM; COMORBIDITY; DRINKING BEHAVIOR; DRUG ALCOHOL INTERACTION; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG SAFETY; ENZYME ACTIVITY; ENZYME INDUCTION; HEMOCHROMATOSIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEREDITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; HYPOGLYCEMIA; HYPOXIA; LIPID METABOLISM; LIVER INJURY; LIVER METABOLISM; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OXIDATION REDUCTION REACTION; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN METABOLISM; REVIEW;

ALCOHOL DRINKING; ALCOHOLISM; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHANOL; HUMANS; LIVER DISEASES, ALCOHOLIC;

EID: 37749053679     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22010     Document Type: Review

References (50)

1. Alcohol use and alcohol use disorders in the United States: main findings from the 2001-2002 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). In: U.S. Alcohol Epidemiologic Data Reference Manual. Vol. 8. National Institute on Alcohol Abuse and Alcoholism Web site. Available at: http://niaaa.census.gov/pdfs/nesarc_drm.pdf. Accessed September 2007.
2. Yoon YH, Yi HY. Surveillance report #75: liver cirrhosis mortality in the United States, 1970-2003. National Institute on Alcohol Abuse and Alcoholism Web site. Available at: http://pubs.niaaa.nih.gov/publications/surveillance75/ Cirr03.htm. Accessed September 2007.
3. Mann RE, Smart RG, Govoni R. The epidemiology of alcohol liver disease. J Natl Inst Alcohol Abuse Alcohol 2003;27:209-219.
4. Li TK, Yin SJ, Crabb DW, O'Connor S, Ramchandani VA. Genetic and environmental influences on alcohol metabolism in humans. Alcohol Clin Exp Res 2001;25:136-144.
5. Li TK, Hewitt BG, Grant BF. Is there a future for quantifying drinking in the diagnosis, treatment, and prevention of alcohol use disorders? Alcohol Alcohol 2007;42:57-63.
6. National Advisory Council on Alcohol Abuse and Alcoholism, summary of meeting, February 4-5, 2004. National Institute on Alcohol Abuse and Alcoholism Web site. Available at: http://www.niaaa.nih.gov/AboutNIAAA/AdvisoryCouncil/ CouncilMinutes/min2-04.htm. Accessed September 2007.
7. Saha TD, Stinson FS, Grant BF. The role of alcohol consumption in future classifications of alcohol use disorders. Drug Alcohol Depend 2007;89:82-92.
8. Barbor TF, de la Fuente JR, Saunders J, Grant M. AUDIT: The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Health Care. Geneva, Switzerland: World Health Organization; 1992.
9. Reuben A. Alcohol and the liver. Curr Opin Gastroenterol 2007;23:283-291.
10. Lelbach WK. Cirrhosis in the alcoholic and its relation to the volume of alcohol abuse. Ann N Y Acad Sci 1975;252:85-105.
11. Caroli J, Mainguet P, Ricordeau P, Foures A. L'importance de la laparoscopic dans la classification anatomo-clinique des cirrhoses du foie. Paper presented at: Cirrhose Alcoolique et Nutritionnelle XXXIIe Congres Français.
12. Pequignot G, Tuyns AJ, Berta JL. Ascitic cirrhosis in relation to alcohol consumption. Int J Epidemiol 1978;7:113-120.
13. Parrish KM, Dufour MC, Stinson FS, Harford TC. Average daily alcohol consumption during adult life among decedents with and without cirrhosis: the 1986 national mortality followback survey. J Stud Alcohol 1993;54:450-456.
14. Kamper-Jorgensen M, Gronbaek M, Tolstrup J, Becker U. Alcohol and cirrhosis: dose - response or threshold effect? J Hepatol 2004;41:25-30.
15. Becker U, Deis A, Sorensen TIA, Gronbaek M, Borch-Johnsen K, Muller CF, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. HEPATOLOGY 1996;23:1025-1029.
16. Bellentani S, Saccoccio G, Costa G, Tiribelli C, Manenti F, Sodde M, et al. Drinking habits as cofactors of risk for alcohol induced liver damage. Gut 1997;41:845-850.
17. Corrao G, Bagnardi V, Zambon A, La Vecchia C. A meta-analysis of alcohol consumption and the risk of 15 diseases. Prev Med 2004;38:613-619.
18. Zakhari S. Overview: how is alcohol metabolized by the body? Alcohol Res Health 2006;29:245-257.
19. Fujino T, Kondo J, Ishikawa M, Morikawa K, Yamamoto TT. Acetyl-CoA synthase 2, a mitochondrial matrix enzyme involved in the oxidation of acetate. JBC 2001;276:11420-11426.
20. Krebs HA, Freedland RA, Hems R, Stubbs M. Inhibition of hepatic gluconeogenesis by ethanol. Biochem J 1969;112:117-124.
21. Gauthier PM, Szerlip HM. Metabolic acidosis in the intensive care unit. Crit Care Clin 2002;18:289-308.
22. Yamanaka H. Alcohol ingestion and hyperuricemia. Nippon Rinsho 1996;54:3369-73.
23. Lieber CS. Alcohol and the liver: 1984 update. HEPATOLOGY 1984;4:1243-1260.
24. French SW. The role of hypoxia in the pathogenesis of alcoholic liver disease. Hepatol Res 2004;29:69-74.
25. Hurly TD, Edenberg HJ, Li TK. The pharmacogenomics of alcoholism. In: Pharmacogenomics: The Search for Individualized Therapies; Weinheim, Germany: Wiley-VCH; 2002:417-441.
26. Zintzaras E, Stefanidis I, Santos M, Vidal F. Do alcohol metabolizing enzyme gene polymorphisms increase the risk of alcoholism and alcoholic liver disease? HEPATOLOGY 2006;43:352-361.
27. Tanaka F, Shiratori Y, Yokosuka O, Imazeki F, Tsukada Y, Omata M. High incidence of ADH2*1/ALDH2*1 genes among Japanese alcohol dependents and patients with alcoholic liver disease. HEPATOLOGY 1996;23:234-239.
28. Chao YC, Young TH, Tang HS, Hsu CT. Alcoholism and alcoholic organ damage and genetic polymorphisms of alcohol metabolizing enzymes in Chinese patients. HEPATOLOGY 1997;25:112-117.
29. Lee HC, Lee HS, Jung SH, Yi SY, Jung HK, Yoon JH, et al. Association between polymorphisms of ethanol-metabolizing enzymes and susceptibility to alcoholic cirrhosis in a Korean male population. J Korean Med Sci 2001;16:745-750.
30. Lorenzo A, Auguet T, Vidal F, Broch M, Olona M, Gutierrez C, et al. Polymorphisms of alcohol-metabolizing enzymes and the risk for alcoholism and alcoholic liver disease in Caucasian Spanish women. Drug Alcohol Depend 2006;84:195-200.
31. Nagata N, Hiyoshi M, Shiozawa H, Shiraishi K, Watanabe N, Tsuda M, et al. Assessment of a difference in ALDH2 heterozygotes and alcoholic liver injury. Alcohol Clin Exp Res 2002;26:11S-14S.
32. Ceccanti M, Attili A, Balducci G, Attilia F, Giacomelli S, Rotondo C, et al. Acute alcoholic hepatitis. J Clin Gastroenterol 2006;40:833-841.
33. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-832.
34. Hezode C, Lonjon I, Roudot-Thoraval F, Pawlotsky JM, Zafrani ES, Dhumeaux D. Impact of moderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C, and specific influence of steatosis: a prospective study. Aliment Pharmacol Ther 2003;17:1031-1037.
35. Anand BS, Currie S, Dieperink E, Bini EJ, Shen H, Ho SB, et al. Alcohol use and treatment of hepatitis C virus: results of a national multicenter study. Gastroenterology 2006;130:1607-1616.
36. Feierman ED, Mehnkov Z, Nanji AA. Induction of CYP3A by ethanol in multiple in vitro and in vivo models. Alcohol Clin Exp Res 2003;27:981-988.
37. Ajani UA, Hennekens CH, Spelsberg A, Manson JE. Alcohol consumption and risk of type 2 diabetes mellitus among US male physicians. Arch Intern Med 2000;160:1025-1030.
38. Wei M, Kampert JB, Gibbons LW, Blair SN, Mitchell T. Alcohol intake and incidence of type 2 diabetes in men. Diabetes Care 2000;23:18-22.
39. Stampfer MJ, Colditz GA, Willen WC, Manson JE, Arky RA, Hennekens CH, et al. A prospective study of moderate alcohol drinking and risk of diabetes in women. Am J Epidemiol 1988;128:549-558.
40. Yoshitsugu M, Sekiya Y, Ihore M. A chronic alcoholic patient with the development of frank diabetes after heavy drinking and perfect improvement following abstinence from alcohol. Arukoru Kenkyuto Yakubutsu Ison 1992;27:276-283.
41. Breslow RA, Smothers BA. Drinking patterns and body mass index in never smokers: National Health Interview Survey, 1997-2001. Am J Epidemiol 2005;161:368-376.
42. Freiberg MS, Vasan RS, Cabral HJ, Ellison RC, Heeren TC. Alcohol consumption and the prevalence of the metabolic syndrome in the U.S.: a cross-sectional analysis of data from the Third National Health and Nutrition Examination Survey. Diabetes Care 2004;27:2954-2959.
43. Raynard B, Balian A, Fallik D, Capron F, Bedossa P, Chaput JC, et al. Risk factors of fibrosis in alcohol-induced liver disease. HEPATOLOGY 2002;35:635-638.
44. Prescott LF. Paracetamol, alcohol and the liver. Br J Clin Pharmacol 2000;49:291-301.
45. Dumortier J, Bellemin B, Jacob P, Berger F, Chevallier M, Scoazec JY, et al. Liver injury due to tetrabamate (Atrium): an analysis of 11 cases. Eur J Gastroenterol Hepatol 2000;12:1007-1012.
46. Campbell S, Timms PM, Maxwell PR, Doherty EM, Rahman MZ, Lean ME, et al. Effect of alcohol withdrawal on liver transaminase levels and markers of liver fibrosis. J Gastroenterol Hepatol 2001;16:1254-1259.
47. Centerholt C, Ekblom M, Odergren T, Borga O, Popescu G, Molz KH, et al. Pharmacokinetics and sedative effects in healthy subjects and subjects with impaired liver function after continuous infusion of clomethiazole. Eur J Clin Pharmacol 2003;59:117-122.
48. Bjornsson E, Nordlinder H, Olsson R. Clinical characteristics and prognosric markers in disulfiram-induced liver injury. J Hepatol 2006;44:791-797.
49. Scott LJ, Figgitt DP, Keam SJ, Waugh J. Acamprostate: a review of its use in the maintenance of abstinence in patients with alcohol dependence. CNS Drugs 2005;19:445-464.
50. Brewer C, Wong VS. Naltrexone: report of lack of hepatotoxicity in acute viral hepatitis, with a review of the literature. Addict Biol 2004;9:81-87.